Nonalcoholic fatty liver disease: Diagnosis, pathogenesis, and management

2014 ◽  
Vol 25 (2) ◽  
pp. 127-132 ◽  
Author(s):  
Metin Basaranoglu ◽  
Necati Ormeci
Keyword(s):  
Liver Disease ◽  
Fatty Liver ◽  
Nonalcoholic Fatty Liver Disease ◽  
Fatty Liver Disease ◽  
Disease Diagnosis ◽  
Nonalcoholic Fatty Liver ◽  
Liver Disease Diagnosis

scholarly journals Use of Mac-2 binding protein as a biomarker for nonalcoholic fatty liver disease diagnosis

2017 ◽  
Vol 1 (8) ◽  
pp. 780-791 ◽  
Author(s):  
Yoshihiro Kamada ◽  
Masafumi Ono ◽  
Hideyuki Hyogo ◽  
Hideki Fujii ◽  
Yoshio Sumida ◽  
...  
Keyword(s):  
Liver Disease ◽  
Fatty Liver ◽  
Nonalcoholic Fatty Liver Disease ◽  
Fatty Liver Disease ◽  
Binding Protein ◽  
Disease Diagnosis ◽  
Nonalcoholic Fatty Liver ◽  
Liver Disease Diagnosis

scholarly journals The Role of Long Non-Coding RNAs (lncRNAs) in the Development and Progression of Fibrosis Associated with Nonalcoholic Fatty Liver Disease (NAFLD)

2018 ◽  
Vol 4 (3) ◽  
pp. 18 ◽  
Author(s):  
Amanda Hanson ◽  
Danielle Wilhelmsen ◽  
Johanna DiStefano
Keyword(s):  
Liver Disease ◽  
Fatty Liver ◽  
Nonalcoholic Fatty Liver Disease ◽  
Fatty Liver Disease ◽  
Molecular Mechanisms ◽  
Disease Diagnosis ◽  
Noninvasive Methods ◽  
Nonalcoholic Fatty Liver ◽  
Potential Applicability ◽  
Non Coding Rnas

Nonalcoholic fatty liver disease (NAFLD) encompasses a spectrum of conditions ranging from hepatic steatosis to inflammation (nonalcoholic steatohepatitis or NASH) with or without fibrosis, in the absence of significant alcohol consumption. The presence of fibrosis in NASH patients is associated with greater liver-related morbidity and mortality; however, the molecular mechanisms underlying the development of fibrosis and cirrhosis in NAFLD patients remain poorly understood. Long non-coding RNAs (lncRNAs) are emerging as key contributors to biological processes that are underpinning the initiation and progression of NAFLD fibrosis. This review summarizes the experimental findings that have been obtained to date in animal models of liver fibrosis and NAFLD patients with fibrosis. We also discuss the potential applicability of circulating lncRNAs to serve as biomarkers for the diagnosis and prognosis of NAFLD fibrosis. A better understanding of the role played by lncRNAs in NAFLD fibrosis is critical for the identification of novel therapeutic targets for drug development and improved, noninvasive methods for disease diagnosis.

Sign in / Sign up

Export Citation Format

Share Document